EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy

被引：0
|
作者：
Michael Lassmann
Heribert Hänscheid
Carlo Chiesa
Cecilia Hindorf
Glenn Flux
Markus Luster
机构：
[1] University Hospital Würzburg,Department of Nuclear Medicine
[2] Istituto Nazionale Tumori,Nuclear Medicine Department
[3] The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,Joint Department of Physics
[4] Sutton,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2008年 / 35卷
关键词：
Dosimetry; Thyroid cancer; SOP;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Pre-therapy Bone Marrow And Lesion Absorbed Dose Estimation Using Different Dosimetry Models In Metastatic Differentiated Thyroid Cancer
    Abuqbeitah, M. M.
    Tanyildizi, H.
    Cavdar, I.
    Demir, M.
    Yeyin, N.
    Vatankulu, B.
    Kabasakal, L.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S221 - S221
  • [22] Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer
    Lassmann, M
    Luster, M
    Hänscheid, H
    Reiners, C
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2005, 46 (05): : 899 - 899
  • [23] Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer
    Jentzen, Walter
    Freudenberg, Lutz
    Eising, Emst G.
    Sormenschein, Wilfried
    Knust, Jochen
    Bockisch, Andreas
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (06): : 1017 - 1023
  • [24] Sites Performing Dosimetry for Selection of Activity for 131I Therapy for Differentiated Thyroid Cancer
    Van Nostrand, Douglas
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (06): : 20N - 22N
  • [25] Previsional and post therapy Red Marrow Dosimetry in differentiated thyroid cancer : a method to optimize treatment and efficacy
    Rossi, G.
    Camarda, M.
    D'Avenia, P.
    Di Nicola, E.
    Montani, L.
    Bartolozzi, C.
    De Angelis, F.
    Dente, A.
    Gasparrini, N.
    Brianzoni, E.
    Fattori, S.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S53 - S54
  • [26] The application of [123I]NaI as a surrogate radiopharmaceutical for the pre-therapeutic dosimetry in differentiated thyroid cancer with [131I]NaI: A preclinical study using the xenograft mouse model
    Kim, S.
    Kim, H.
    Song, I.
    Park, H.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S146 - S146
  • [27] Predictive pretherapy blood and bone marrow dosimetry for thyroid cancer patients prepared with rhTSH injection
    Al Jabri, A.
    Cooke, J.
    Cournane, S.
    O'Reilly, G.
    Healy, M. L.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 (SUPPL 4) : 96 - 96
  • [28] Bone marrow radiation dosimetry of high dose 131I treatment in differentiated thyroid carcinoma patients
    Parlak, Y.
    Demir, M.
    Cavdar, I.
    Ereees, S.
    Gumuser, G.
    Uysal, B.
    Kaya, G. Capa
    Koc, M.
    Sayit, E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2016, 14 (02): : 99 - 104
  • [29] Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer
    Jentzen, Walter
    Hobbs, Robert F.
    Stahl, Alexander
    Knust, Jochen
    Sgouros, George
    Bockisch, Andreas
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (05) : 884 - 895
  • [30] Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer
    Walter Jentzen
    Robert F. Hobbs
    Alexander Stahl
    Jochen Knust
    George Sgouros
    Andreas Bockisch
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 : 884 - 895
12345